ArticleResearch and practice in thrombosis and haemostasis2026
The viability and coagulation function of storing platelets can be maintained in plasma without cryoprotectants at -80 °C.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To prolong the storage period of platelets, dimethyl sulfoxide (DMSO) has been used for platelet cryopreservation at -80 °C to prevent cold storage lesions. Nevertheless, it is important to note that DMSO is a toxic chemical agent that may cause adverse effects and potential safety concerns for clinical applications. Therefore, many studies have attempted to reduce the DMSO concentration used for platelet cryopreservation. Based on our previous findings regarding the stability of platelets in platelet-rich plasma stored at -80 °C for 1 month, it is imperative to explore the cryopreservation of platelets in plasma. Objectives: This study aimed to evaluate the feasibility of storing apheresis platelets in plasma at -80 °C as a supplemental solution in the absence of cryoprotectants, such as DMSO. Methods: We used a comprehensive approach, analyzing platelet count, morphology, mitochondrial structure, and metabolomic and proteomic profiles to assess storage lesions. Results: Our findings revealed that platelets stored at -80 °C in plasma maintained a stable cell count and procoagulant function, comparable with those stored with DMSO. Proteomic analysis showed that the fundamental protein composition essential for platelet clotting function was largely preserved, while metabolomic analysis suggested that metabolism had a minimal impact on platelet homeostasis. Conclusion: These results demonstrate that storage in plasma at -80 °C effectively preserves platelet viability and functionality over a short period. This study highlights the potential for developing supplementary storage strategies as alternatives to conventional preservation methods, which could improve platelet availability in transfusion medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.